What is Biosystems International?
Biosystems International operates at the intersection of biotechnology and clinical diagnostics, specializing in the development of advanced screening tools for early-stage cancer detection. The company's core competency lies in its innovative multiplex ELISA technology, which facilitates the precise identification of protein biomarkers associated with lung malignancy. Through its flagship product, Pulmolisa, the organization provides a non-invasive, blood-based diagnostic solution that offers a significant improvement over traditional, more invasive screening methodologies. By targeting the early detection market, Biosystems International addresses a high-growth segment of the healthcare industry, positioning itself as a vital partner for clinical institutions seeking to improve patient survival rates through timely intervention and accurate differential diagnosis.
How much funding has Biosystems International raised?
Biosystems International has raised a total of $8.5M across 2 funding rounds:
Angel/Seed
$3.9M
Unspecified
$4.6M
Angel/Seed (2005): $3.9M with participation from Societe Generale
Unspecified (2008): $4.6M, investors not publicly disclosed
Key Investors in Biosystems International
Societe Generale
A prominent French multinational financial services institution providing comprehensive banking, insurance, and investment management solutions to global markets.
Undisclosed Investor
An undisclosed entity participating in the strategic financing round to support the company's long-term growth objectives.
What's next for Biosystems International?
Looking ahead, Biosystems International is poised to leverage its recent capital injection to broaden the clinical validation of its diagnostic suite. The strategic roadmap likely involves scaling manufacturing processes to meet anticipated demand from healthcare networks and deepening its research into additional protein epitope profiles. As the company matures, the focus will shift toward securing broader regulatory approvals and establishing strategic partnerships with global diagnostic laboratories. This expansion phase is critical for transitioning from a research-centric entity to a commercial-scale enterprise, ensuring that its diagnostic innovations are integrated into routine clinical workflows for high-risk lung cancer screening.
See full Biosystems International company page
